Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.

A new study published in the journal of CHEST showed that benralizumab reduces exacerbations, especially in older individuals ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory ...

More patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with placebo, despite similar levels of continuing symptoms in the two groups at ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...

After three months of treatment, four times fewer people taking benralizumab had suffered an asthma or COPD attack, compared to people taking the steroid prednisolone. “This could be a game ...

Please provide your email address to receive an email when new articles are posted on . Benralizumab induces depletion of eosinophils and mepolizumab reduces activation. The study followed ...

(RTTNews) - Researchers at King's College London have found a new treatment for asthma attacks, which could be a "game-changer" for the patients. Lead investigator Prof Mona Bafadhel, of King's ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

Bangalore: AstraZeneca Pharma India Limited has received regulatory approval from the Central Drugs Standard Control ...

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.